SEC Comment Letter 0000000000-25-003888 to CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: April 11, 2025 · CIK: 0001729427 · Accession: 0000000000-25-003888
AI Filing Summary & Sentiment
Reasoning
Letter
Re: CNS Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted April 7, 2025 CIK No. 0001729427 Dear John Climaco:
April 11, 2025
John Climaco Chief Executive Officer CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Cavas S. Pavri
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 11, 2025 John Climaco Chief Executive Officer CNS Pharmaceuticals, Inc. 2100 West Loop South, Suite 900 Houston, TX 77027 Re: CNS Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted April 7, 2025 CIK No. 0001729427 Dear John Climaco: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri </TEXT> </DOCUMENT>